ArticlePloS one2025
Aldo-keto reductase family 1 member C3 (AKR1C3) gene polymorphism (rs12529) is associated with breast cancer in Bangladeshi population: A case-control study and computational investigation.
Article in PloS one, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- A comprehensive in silico investigation into the deleterious nonsynonymous single nucleotide polymorphisms of the human transcription factor EB (TFEB) gene and their predicted association with cancer.Journal, genetic engineering & biotechnology · 2026Article
- Revolutionizing Breast Cancer Treatment: Harnessing Ehrlich Ascites Carcinoma Model, Cancer Metabolism, and Nanotechnology-Enhanced Chemotherapy for Improved Patient Outcomes.Cell biochemistry and biophysics · 2026Review
- Comprehensive analysis of the deleterious nonsynonymous, non-coding SNPs and cancer variants of human aldo-keto reductase type 1 (AKR1C1) protein and their probable association with disease risk and progression: a computational study.Biochemistry and biophysics reports · 2026Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Breast cancer is defined as the unchecked growth of breast cells, with imbalances in prostaglandin and steroid hormone metabolism contributing to disease risk by altering prostaglandin types and forms (strong and weak) of steroid hormones. The AKR1C3 enzyme plays a key role in managing these metabolic processes. This study investigated the association between the AKR1C3 gene polymorphism (rs12529) and the risk of developing breast cancer in Bangladeshi individuals. A case-control investigation was conducted with a total of 620 samples, involving 310 individuals diagnosed with breast cancer and 310 healthy subjects. Herein, DNA extraction was performed via an organic process, whereas genotyping was employed via the PCR‒RFLP technique. Statistical assessments were conducted to analyze the association of polymorphisms, while molecular dynamics simulation and diverse computational techniques were employed to anticipate the functional and structural impacts of the SNP. Our study discovered that the rs12529 polymorphism of the AKR1C3 gene has an enhanced risk of susceptibility to breast malignancy (p = 0.016, OR = 1.97, 95% CI = 1.22 to 3.16 for the GG genotype in additive model 2). The recessive model (GG vs CC+CG) also showed an enhanced risk of susceptibility to breast malignancy (p = 0.0004, OR = 1.95, 95% CI = 1.40 to 2.73). In both premenopausal women and postmenopausal women, the GG genotype (for the recessive model) significantly increased breast cancer risk by 1.92-fold and 1.95-fold, respectively. However, no significant associations were observed regarding tumor grade or size in breast cancer development. In-silico analyses indicated that the H5Q (rs12529) mutation may decrease protein stability but is typically tolerated or functionally neutral. Molecular dynamics simulations revealed that H5Q leads to increased structural fluctuations and surface exposure, potentially causing the mutant AKR1C3 enzyme to operate differently from the wild type. In conclusion, rs12529 significantly increases the incidence of breast cancer in the population of Bangladesh. Computational analyses further revealed that the H5Q (rs12529) mutation in AKR1C3 leads to decreased stability and altered functional changes with notable conformational changes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.